220 likes | 685 Views
NATIONAL DRUG POLICY. Access to medicines. Argentina, 2003. NATIONAL DRUG POLICY. Prescription by generic name of drugs Free essential drugs supply program (REMEDIAR PROGRAM) Priority Programs Protection: The ARV case. 85%. 32%. 6.000. 5.754. 24.532. 25.000. May 2002. 5.000.
E N D
NATIONAL DRUG POLICY Access to medicines Argentina, 2003
NATIONAL DRUG POLICY • Prescription by generic name of drugs • Free essential drugs supply program (REMEDIAR PROGRAM) • Priority Programs Protection: The ARV case
85% 32% 6.000 5.754 24.532 25.000 May 2002 5.000 May 2003 20.000 18.555 4.000 3.113 15.000 Monthly Sales -Units (000)- Monthly Sales -Units (000)- 3.000 10.000 2.000 5.000 1.000 - - Ethical Market OTC market CONSUMPTION IMPACT ON RETAIL PHARMACY Source: Health Ministry based on IMS Health
REMEDIAR: OBJECTIVES • To provide free essential drug to 15,000,000 poor people at every Primary Health Care Center (PHCC) (6.000 centers) • To strengthen the Primary Health Care Strategy • To promote healthy policies with social participation
REMEDIAR: Characteristics • The medicine kit delivered contains 48 essential drugs, covering 80% of medical consults at PHCCs. • Each kit has been designed to supply essential drugs for about 300 medical consults. • REMEDIAR stimulates domestic pharmaceutical industry and improves quality standards
REMEDIAR PROGRAM FOCUS Source: Ministry of Health
REMEDIAR PROGRAM IS AN EQUITABLE AND EFFICIENT ANSWER, BECAUSE: • It guarantees the access to medicines • It is financially sustainable • It is technically consistent • It is federal • It is an adequate answer to emergency • It promotes a lasting reform • It allows efficient purchases • It has a high redistributive impact • It has a strict evaluation and monitoring mechanism • It promotes the rational use of drugs
PRIORITY PROGRAMS PROTECTION The case of ARV
JOINT NEGOTIATION OF ARV PRICES • The process has the support of Andean Health Organism (ORAS/CONHU), World Health Organization/Pan American Health Organization (WHO/PAHO) and UNAIDS. • Doctors Without Borders (MSF), International Red Cross and Latin American Network of People Living with HIV/AIDS,were present as observers. • The higherpricereduction obtained was 92% and the minimum was 10% • Potential joint savings for the participating countries (10 countries), could be around $148 US million dollars (76% of regional ARV expenditure) • These substantial savings will annually allow that 150,000 more people living with AIDS in the region to be assisted.
ARV PRICES NEGOTIATION OUTCOMES (LIMA, PERU -JUNE 2003-) Highest tritherapies cost before and after negotiation
NATIONAL DRUG POLICY Access and Savings Prescription by generic name 3,000,000 more people U$S 324 millions 11,000,000 poor people U$S 288 millions REMEDIAR Program 4,500 more patients U$S 6 millions Price negotiation